Federated Hermes, Inc. Curis Inc Transaction History

Federated Hermes, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.57 - $0.99 $4,496 - $7,810	-7,889 Reduced 88.34%	1,041 $0
Q1 2023 May 08, 2023	SELL	$0.51 - $0.78 $3,153 - $4,823	-6,184 Reduced 40.92%	8,930 $5,000
Q4 2022 Feb 13, 2023	BUY	$0.47 - $17.22 $1,900 - $69,620	4,043 Added 36.52%	15,114 $8,000
Q3 2022 Nov 14, 2022	SELL	$0.74 - $15.01 $207,176 - $4.2 Million	-279,968 Reduced 96.2%	11,071 $8,000
Q2 2022 Aug 15, 2022	BUY	$0.71 - $2.43 $5,179 - $17,726	7,295 Added 2.57%	291,039 $287,000
Q1 2022 May 13, 2022	BUY	$2.31 - $5.13 $655,448 - $1.46 Million	283,744 New	283,744 $675,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.